Stock IXHL INCANNEX HEALTHCARE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Incannex Healthcare Inc.

Equities

IXHL

US45333F1093

Delayed Nasdaq
Other stock markets
 11:23:24 2024-05-31 EDT 		5-day change 1st Jan Change
2.93 USD -2.01% Intraday chart for Incannex Healthcare Inc. +5.39% -36.86%
05-30 Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea CI
05-15 Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
CI
Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
CI
Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder
CI
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
CI
Incannex Healthcare Completes Pre-Investigational New Drug Meeting on CannQuit-N With US FDA
MT
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N
CI
Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
CI
Incannex Completes Dosing and Therapy in Phase 2 ?Psigad? Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder
CI
Incannex Healthcare Gets Institutional Review Board Approval For IHL-42X Drug Trial
MT
Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
CI
Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia
CI
Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea
CI
Incannex Healthcare Inc. Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Incannex Healthcare Inc. Reports Earnings Results for the Half Year Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IXHL Stock
  4. News Incannex Healthcare Inc.
  5. Highlights